Clinical trials: Active Psoriatic Arthritis
Psoriatic Arthritis (PsA)
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis
This study will investigate if the study medicine FT2109 can treat symptoms of active Psoriatic Arthritis (PsA). This study assesses the safety and efficacy of FT2109 in adult participants with active PsA who may or may not have…
- Trial name
- NCT07869134
- Testing
- FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2
- Volunteers
- 210 people
- Sponsor
- Forward Therapeutics
Psoriasis Vulgaris, Active Psoriatic Arthritis
Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis
This is an open-label study to evaluate the effects of bimekizumab in patients with psoriasis vulgaris and who also have active psoriatic arthritis (PsA).
- Trial name
- NCT05499416
- Testing
- Bimekizumab
- Sponsor
- Innovaderm Research Inc.
Psoriatic Arthritis
Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.
The purpose of this study was to assess the efficacy and safety of secukinumab in Chinese participants with active Psoriatic arthritis (PsA ) compared to placebo.
- Trial name
- NCT04711902
- Testing
- AIN457
- Where
- 12 sites in China
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA
EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries
This is a non-interventional, post-marketing, observational study (PMOS) in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA, Rheumatoid Arthritis (RA
- Trial name
- EviraEAST (NCT01078402)
- Where
- 163 sites in Croatia, Hungary and 5 more
- Volunteers
- 809 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Pediatric Arthritis Study of Certolizumab Pegol
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
- Trial name
- PASCAL (NCT01550003)
- Testing
- Certolizumab Pegol (CZP)
- Where
- 36 sites in United States, Argentina and 5 more
- Volunteers
- 193 people
- Sponsor
- UCB BIOSCIENCES GmbH
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs.
- Trial name
- NCT04908202
- Testing
- Deucravacitinib
- Where
- 183 sites in United States, Argentina and 19 more
- Volunteers
- 670 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
- Trial name
- SPIRIT-P2 (NCT02349295)
- Testing
- Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W
- Where
- 109 sites in United States, Australia and 8 more
- Volunteers
- 363 people
- Sponsor
- Eli Lilly and Company
Juvenile Idiopathic Arthritis
Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
This is a multicenter, non-interventional, cohort study in pediatric patients with active juvenile enthesitis-related or psoriatic arthritis
- Trial name
- Toddler (NCT06431750)
- Testing
- Secukinumab
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
- Trial name
- STAR (NCT04929210)
- Testing
- Guselkumab
- Where
- 242 sites in United States, Argentina and 24 more
- Volunteers
- 411 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
HUmira in Psoriatic Arthritis
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis, which has a estimated prevalence of 0.3 - 1 %.
- Trial name
- HUPSA (NCT01465438)
- Testing
- Adalimumab
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Rheumatoid Arthritis, Psoriatic Arthritis
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment
The aim of this study is to examine the associations between inflammatory disease activity and endothelial function in rheumatoid arthritis (RA) and spondyloarthritis patients treated with methotrexate and Tumor Necrosis Factor…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Endothelial Dysfunction
- Trial name
- PSARA (NCT00902005)
- Where
- Norway
- Volunteers
- 145 people
- Sponsor
- Revmatismesykehuset AS
Psoriatic Arthritis
Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.
The purpose of this study is to define cut-off values of the most widely used composite scores and patient-reported outcomes, for levels corresponding to remission/low disease activity and for changes in levels corresponding to…
- Trial name
- ReFlaP (NCT03119805)
- Where
- 22 sites in United States, Austria and 12 more
- Volunteers
- 466 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Psoriatic Arthritis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide…
- Trial name
- TOGETHER-PsA (NCT06588296)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 86 sites in United States, Puerto Rico
- Volunteers
- 279 people
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
The purpose of this study was to provide up to 52 weeks of efficacy, safety and tolerability data to support registration of intravenous (i.v.) secukinumab (Initial dose of 6 mg/kg at Baseline (BSL) followed thereafter with 3…
- Trial name
- INVIGORATE 2 (NCT04209205)
- Testing
- AIN457 6 mg/kg i.v., AIN457 3 mg/kg
- Where
- 80 sites in United States, Brazil and 13 more
- Volunteers
- 381 people
- Sponsor
- Novartis Pharmaceuticals
Arthritic Psoriasis
Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)
Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks.
- Trial name
- NCT07706530
- Testing
- CBP-0276 capsules 100mg
- Where
- Mexico
- Volunteers
- 240 people
- Sponsor
- Clarent Biopharma, Inc.
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of SPY072 in Rheumatic Disease
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
- Trial name
- SKYWAY-RD (NCT07148414)
- Testing
- SPY002-072
- Where
- 64 sites in United States, Bulgaria and 6 more
- Volunteers
- 285 people
- Sponsor
- Spyre Therapeutics, Inc.
Psoriatic Arthritis
A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis
This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled, dose finding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to investigate the efficacy, tolerability, safety…
- Trial name
- NCT04713072
- Testing
- ABY-035
- Where
- 32 sites in Austria, Belgium and 5 more
- Volunteers
- 129 people
- Sponsor
- ACELYRIN Inc.
Spondyloarthritis (SpA), Psoriatic Arthritis (PsA)
Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
The aim of the present work is to assess the nutritional status among different rheumatic diseases patients and to study its association with the corresponding diseases activity.
- Conditions
- Spondyloarthritis (SpA), Psoriatic Arthritis (PsA), Systemic Lupus Erythematous (SLE), Systemic Sclerosis (SSc)
- Trial name
- NCT07277491
- Where
- Egypt
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Cairo University